HIV Treatment Strategies

Conference Coverage

The Latest

David Alain Wohl recaps CROI 2021 research during a video interview

CROI 2021 Highlights: New HIV Research With Clinical Impact

Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.

By Myles Helfand
clinical trial

Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists

A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.

By Terri Wilder, M.S.W.

Long-Acting ART Is Here. How Do We Make It Work for Our Patients?

Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.

By Larry Buhl
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

Broadly Neutralizing Antibodies for HIV? If We Can Do It for COVID ...

David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

CROI 2021 Takeaway: Long-Acting Antiretrovirals for HIV Treatment

David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.

By David Alain Wohl, M.D.
injection vials

Long-Acting HIV Treatment and PrEP Pipeline Update: So Many Formulations!

CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.

By Larry Buhl
CROI 2021 virtual oral abstract session featuring speakers in tiny video boxes

CROI 2021 Data Bites: HIV Treatment and the Care Continuum

Our bite-sized study summaries include new research on antiretrovirals in development, trends in antiretroviral initiation speed and viral suppression rates in the U.S., and the link between gender-affirming surgery and an undetectable viral load.

By Myles Helfand and Larry Buhl
video conference

This Week in HIV Research: While You Were CROI-ing

March 11, 2021: Anticholinergic medications and neurocognitive issues; weight gain and dolutegravir in older men; drug interaction risks on B/F/TAF; real-world efficacy of HBV-active HIV treatment.

By Barbara Jungwirth and Myles Helfand
CROI 2019

New COVID-19 Research and HIV Intervention Breakthroughs Are on the Menu at CROI 2021

Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.

By Larry Buhl

Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions

Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.

By Larry Buhl